| Related Articles |
Identifying Novel Sepsis Subphenotypes Using Temperature Trajectories.
Am J Respir Crit Care Med. 2019 Feb 21;:
Authors: Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM
Abstract
RATIONALE: Sepsis is a heterogeneous syndrome, and identifying clinically relevant subphenotypes is essential.
OBJECTIVES: To identify novel subphenotypes in hospitalized patients with infection using longitudinal temperature trajectories.
METHODS: In the model development cohort, inpatient admissions meeting criteria for infection in the emergency department and receiving antibiotics within 24 hours of presentation were included. Temperature measurements within the first 72 hours were compared between survivors and non-survivors. Group-based trajectory modeling was performed to identify temperature trajectory groups, and patient characteristics and outcomes were compared between the groups. The model was then externally validated at a second hospital using the same inclusion criteria.
MEASUREMENTS AND MAIN RESULTS: 12,413 admissions were included in the development cohort and 19,053 were included in the validation cohort. In the development cohort, four temperature trajectory groups were identified: "hyperthermic, slow resolvers" (n=1,855; 14.9% of the cohort), "hyperthermic, fast resolvers" (n=2,877; 23.2%), "normothermic" (n=4,067; 32.8%) and "hypothermic" (n=3,614; 29.1%). The "hypothermic" subjects were the oldest, had the most comorbidities, the lowest levels of inflammatory markers, and the highest in-hospital mortality rate (9.5%). The "hyperthermic, slow resolvers" were the youngest, had the fewest comorbidities, the highest levels of inflammatory markers, and a mortality rate of 5.1%. The "hyperthermic, fast resolvers" had the lowest mortality rate (2.9%). Similar trajectory groups, patient characteristics, and outcomes were found in the validation cohort.
CONCLUSION: We identified and validated four novel subphenotypes of patients with infection, with significant variability in inflammatory markers and outcomes.
PMID: 30789749 [PubMed - as supplied by publisher]